TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07470853: A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Sponsor: Whitehawk Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 265 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07470853 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07470853 Rescue Dossier →